BusinessMelinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA PathogensBy Nasdaq OMXSep 18, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug DesignBy Nasdaq OMXApr 21, 2017, 1:56 PM UTC
